Compare BridgeBio Pharma Inc (BBIO) vs Howmet Aerospace Inc (HWM) Price & Performance

BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.

Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.

Howmet Aerospace (HWM) trades at $271.28, up 0.16% on the day, with a neutral technical signal but strong fundamental performance. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $1.22 exceeding expectations. Revenue growth and robust profit margins, including a 20.22% net income margin, support its premium valuation multiples. Recent news highlights strength in commercial aerospace demand as a key growth driver.

The outlook remains positive given analyst consensus with 84% buy ratings and a $317.63 price target, suggesting ~17% upside. However, elevated valuation ratios like a P/E of 64.22 pose risks if growth slows. Key catalysts include Q2 2026 results on August 6, 2026, while reliance on aerospace cycles and competitive pressures are monitoring points for investors.